Abstract
A significant proportion of patients with gastro‐oesophageal reflux disease (GERD) haveHelicobacter pyloriinfection, but it is unclear whether or notH. pylorishould be treated in this clinical setting. The aim of this review was to critically assess the relationship betweenH. pyloriand GERD and its potential implications for the management of GERD. Data for this review were gathered from the following sources up to April 1998—the biomedical database MEDLINE, a detailed review of medical journals, and a review of abstracts submitted to relevant international meetings.On average, 40% of GERD patients carryH. pyloriinfection, with a reported infection prevalence ranging from 16% to 88%. To date, there has been no reported controlled trial of effectiveH. pyloritherapy in GERD. GERD has been reported to developde novofollowing the cure ofH. pyloriin peptic ulcer disease.In the presence ofH. pylori, proton pump inhibitor therapy appears to accelerate the development of atrophic corpus gastritis, a potentially precancerous condition. Conversely, proton pump inhibitor therapy seems to become less effective after cure ofH. pylori. The mechanisms underlying these important contrasting phenomena are poorly understood.The relationship betweenH. pyloriand GERD is complex, and it is difficult to give definitive guidelines on the management ofH. pyloriinfection in GERD. Controlled trials ofH. pyloritherapy in GERD are urgently needed, as well as further long‐term data on both the natural history of gastric histopathological changes in theH. pylori‐positive GERD patient treated with proton pump inhibitors, and the impact ofH. pyloristatus on the clinical efficacy of antisecretory therapy. Pending these data, it is perhaps advisable to advocate cure ofH. pyloriin young patients with proton pump inhibitor‐dependent GERD who, in the absence of anti‐reflux surgery, are faced with the likelihood of long‐term medical therapy.

This publication has 64 references indexed in Scilit: